Agenus to Host Annual Meeting of Stockholders
Business Wire - Wed Apr 16, 10:45AM CDT
Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014. The meeting will be held at the company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
Positive Results on Intercept Pharma's OCA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:30PM CDT
Intercept Pharma announced positive additional data from the phase III study on obeticholic acid.
The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
Glaxo Stops MAGE-A3 Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:14PM CDT
Glaxo announced that it has decided to terminate the phase III MAGRIT study on its MAGE-A3 cancer immunotherapeutic.
Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 02, 8:22AM CDT
Let's take a look a four stocks -- MannKind , GlaxoSmithKline , Myriad Genetics , and Alnylam Pharmaceuticals -- all of which could loom large in health care headlines this Wednesday morning. FDA advisory panel recommends the approval of...
Update on GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer
Business Wire - Wed Apr 02, 1:01AM CDT
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline's (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients, which contains Agenus'QS-21 Stimulon(R) adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.
Agenus (AGEN) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 5:47AM CDT
Agenus (AGEN) Sees Hammer Chart Pattern: Time to Buy?
The Week's Worst Clinical Failures
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
While there were plenty of winners last week, two losers stand out. The first failure belongs to GlaxoSmithKline . This giant is leading the industry with 20 new molecular entity approvals over the past six years. But its recent failure shows how...
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Agenus to Present at the 4th Annual Cancer Immunotherapy Conference
Business Wire - Wed Mar 26, 6:00AM CDT
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus' checkpoint modulator portfolio and immuno-oncology strategy at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. On March 27, 2014, a presentation on Checkpoint Modulators is scheduled for 8:30 am Eastern Time and a corporate presentation is scheduled for 2:15 pm Eastern Time.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
Stock to Watch: Antigenics Down 10.2% (AGEN)
Comtex SmarTrend(R) - Mon Mar 24, 12:49PM CDT
Antigenics (NASDAQ:AGEN) is one of today's worst performing low-priced stocks, down 10.2% to $3.27 on 1.0x average daily volume. Thus far today, Antigenics has traded 1.3 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-10.2% to the Dow's -0.3%) and underperformed the S&P 500 (-10.2% to the S&P's -0.6%) during today's trading.
Why Agenus (AGEN) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:46AM CDT
If you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Agenus.
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Glaxo's MAGE-A3 Candidate Disappoints Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:36PM CDT
Glaxo announced disappointing data from the phase III MAGRIT study on its MAGE-A3 cancer immunotherapeutic.
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Guess and Lennar are big market movers
AP - Thu Mar 20, 4:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Agenus Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 1:33PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agenus , a biopharmaceutical company...
Why Agenus (AGEN) Is Down Big Today
at The Street - Thu Mar 20, 10:22AM CDT
Shares of Agenus (AGEN) fall on Thursday following the news that the latest round of Phase 3 non small cell lung immunotherapeutic trials had failed to meet its first or secondary co-primary endpoint.